Cargando…
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Neuroblastoma is characterized by a relative paucity of recurrent somatic mutations at diagnosis. However, recent studies have shown that the mutational burden increases at relapse, likely as a result of clonal evolution of mutation-carrying cells during primary treatment. To inform the development...
Autores principales: | Padovan-Merhar, Olivia M., Raman, Pichai, Ostrovnaya, Irina, Kalletla, Karthik, Rubnitz, Kaitlyn R., Sanford, Eric M., Ali, Siraj M., Miller, Vincent A., Mossé, Yael P., Granger, Meaghan P., Weiss, Brian, Maris, John M., Modak, Shakeel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172533/ https://www.ncbi.nlm.nih.gov/pubmed/27997549 http://dx.doi.org/10.1371/journal.pgen.1006501 |
Ejemplares similares
-
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023) -
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
por: Berko, Esther R., et al.
Publicado: (2023) -
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-G(D2) immunotherapy and isotretinoin
por: Kushner, Brian H., et al.
Publicado: (2015) -
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020) -
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine
por: Sun, Weili, et al.
Publicado: (2012)